Lantheus wins FDA approval for Tauklarify tau PET imaging in Alzheimer’s evaluation
FDA approves Lantheus’ Tauklarify for Alzheimer’s tau PET imaging. See what the scan detects, where errors arise and what could limit access.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
Nanochon can now test Chondrograft in Panama, but five patients could decide what happens next
Nanochon gains Panama authorization for a five-patient Chondrograft study as its cartilage implant moves deeper into first-in-human testing.
Medical Devices & Diagnostics
Lantheus adds TAUKLARIFY to Alzheimer’s imaging toolkit after FDA approval
FDA approves TAUKLARIFY for tau PET imaging in Alzheimer’s evaluation. See how Lantheus’ new tracer fits into the evolving diagnostic market.
Medical Devices & Diagnostics
Can a wearable make chronic pain measurable? Adaptyx and Attune put five biomarkers to the test
Adaptyx and Attune begin a $4 million ARPA-H-backed study testing continuous biomarkers and focused ultrasound in 100 adults with chronic pain.
Medical Devices & Diagnostics
VB Spine closes Augmedics CT-Fluoro deal as xvision targets wider AR spine surgery adoption
VB Spine has closed its CT-Fluoro deal with Augmedics. See why the xvision addition could widen access to AR spine navigation.
Medical Devices & Diagnostics
Restylane Shaype has cleared Europe, but can Galderma turn its “bone-mimicking” filler into a new chin-shaping standard?
Galderma’s Restylane Shaype gains EU MDR approval for chin augmentation, bringing its high-firmness NASHA HD filler into Europe.
Medical Devices & Diagnostics
Labcorp gets FDA approval for PGDx elio tissue complete CDx in BRAF-mutated melanoma
Labcorp Holdings Inc. (NYSE: LH) announced on August 10, 2026 that the U.S. Food and Drug Administration has approved PGDx elio tissue complete CDx as a companion diagnostic for identifying melanoma patients whose tumors carry BRAF V600E or BRAF V600K mutations and who may benefit from FDA-approved BRAF inhibitors or approved BRAF and MEK inhibitor
Medical Devices & Diagnostics
MindMaze Therapeutics has finished its portfolio reset, but why is half of the CHF 8m Neuro.io financing still pending?
MindMaze Therapeutics finishes its neurology refocus while CHF 4 million of Neuro.io funding shifts to September and November. See what comes next.
Medical Devices & Diagnostics
Can a blood test reveal which neurons are dying? Renew Biotechnologies’ NeuroLens study takes a significant step forward
Renew Biotechnologies has published peer-reviewed proof-of-concept research showing that native cell-free DNA methylation sequencing can recover neuron-associated blood signals that differ across Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. The results strengthen the scientific rationale behind its NeuroLens platform, but the decisive next step is independent, prospective validation in larger and more diverse patient
Medical Devices & Diagnostics
Nipro says ELISIO-HX can improve dialysis without new machines. Will better toxin removal translate into better outcomes?
Nipro Corporation has commercially launched its FDA-cleared ELISIO-HX dialyzer in the United States, offering dialysis providers a medium cut-off membrane designed to remove larger uremic toxins through existing hemodialysis equipment and workflows.